Emaldo and GeneSense Lead HKIC's Investment Strategy in Southeast Asia
Friday, 13 September 2024, 11:30
Strategic Investments in Biotech and Health
The Hong Kong Investment Corporation (HKIC) has identified key projects for investment that leverage local technological innovation. Emaldo, a consumer power station developer, and GeneSense, specializing in gene-sequencing technology, are pivotal players.
Innovative Startups Fueling Growth
- Ninenovo: A wearable device developer based in Guangdong, recently expanded into Hong Kong Science Park with a US$279 smart ring for sleep data.
- GeneSense: Utilizing AI for efficient gene sequencing, expanding R&D in Hong Kong.
- Emaldo: Home power solutions from Olstykke tapping into Hong Kong's top talent.
CEO Clara Chan emphasizes collaboration with venture capital funds and academic institutions to nurture innovations, ensuring Hong Kong's leadership in the global biotech landscape.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.